[{"address1": "Yalelaan 62", "city": "Utrecht", "zip": "3584 CM", "country": "Netherlands", "phone": "31 85 016 3100", "website": "https://www.lavatherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.", "fullTimeEmployees": 37, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen Allen Hurly M.B.A., M.Sc.", "age": 56, "title": "CEO, President & Executive Director", "yearBorn": 1968, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Fred M. Powell CPA", "age": 63, "title": "Chief Financial Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Oxana  Polyakova Ph.D.", "title": "Chief Scientific Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Garabedian J.D.", "age": 48, "title": "General Counsel & Corporate Secretary", "yearBorn": 1976, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Wouter van Hunnik", "title": "VP & Head of Human Resources", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hans  van der Vliet M.D., Ph.D.", "age": 49, "title": "Head of Innovation", "yearBorn": 1975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ton  Adang Ph.D.", "age": 63, "title": "Chief Development Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.41, "open": 1.42, "dayLow": 1.39, "dayHigh": 1.505, "regularMarketPreviousClose": 1.41, "regularMarketOpen": 1.42, "regularMarketDayLow": 1.39, "regularMarketDayHigh": 1.505, "payoutRatio": 0.0, "beta": 0.475, "forwardPE": -0.742268, "volume": 219616, "regularMarketVolume": 219616, "averageVolume": 485022, "averageVolume10days": 2305310, "averageDailyVolume10Day": 2305310, "bid": 1.41, "ask": 1.46, "bidSize": 2, "askSize": 2, "marketCap": 37870128, "fiftyTwoWeekLow": 0.85, "fiftyTwoWeekHigh": 4.21, "priceToSalesTrailing12Months": 5.1559057, "fiftyDayAverage": 1.02638, "twoHundredDayAverage": 1.6393, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -34723924, "profitMargins": 0.0, "floatShares": 10135243, "sharesOutstanding": 26298700, "sharesShort": 25121, "sharesShortPriorMonth": 61042, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.001, "heldPercentInsiders": 0.40395, "heldPercentInstitutions": 0.38555, "shortRatio": 0.79, "shortPercentOfFloat": 0.0016, "impliedSharesOutstanding": 26298700, "bookValue": 1.255, "priceToBook": 1.1474104, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -27642000, "trailingEps": -1.01, "forwardEps": -1.94, "enterpriseToRevenue": -4.728, "enterpriseToEbitda": 1.264, "52WeekChange": -0.44488192, "SandP52WeekChange": 0.121255875, "quoteType": "EQUITY", "currentPrice": 1.44, "targetHighPrice": 3.099675, "targetLowPrice": 1.5460455, "targetMeanPrice": 2.2372699, "targetMedianPrice": 2.0660887, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 78884000, "totalCashPerShare": 3.0, "ebitda": -27476000, "totalDebt": 6290000, "quickRatio": 5.257, "currentRatio": 5.364, "totalRevenue": 7345000, "debtToEquity": 19.065, "revenuePerShare": 0.271, "returnOnAssets": -0.18031, "returnOnEquity": -0.63118, "grossProfits": 7191000, "freeCashflow": -18466376, "operatingCashflow": -28604000, "grossMargins": 0.97903, "ebitdaMargins": 0.0, "operatingMargins": -3.81743, "financialCurrency": "USD", "symbol": "LVTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "postMarketTime": 1741388428, "regularMarketTime": 1741381201, "exchange": "NMS", "messageBoardId": "finmb_546792242", "exchangeTimezoneName": "America/New_York", "marketState": "CLOSED", "regularMarketChangePercent": 2.127666, "regularMarketPrice": 1.44, "postMarketChangePercent": -0.694452, "postMarketPrice": 1.43, "postMarketChange": -0.0100001, "regularMarketChange": 0.03000009, "regularMarketDayRange": "1.39 - 1.505", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 485022, "fiftyTwoWeekLowChange": 0.59000003, "fiftyTwoWeekLowChangePercent": 0.69411767, "fiftyTwoWeekRange": "0.85 - 4.21", "fiftyTwoWeekHighChange": -2.77, "fiftyTwoWeekHighChangePercent": -0.65795726, "fiftyTwoWeekChangePercent": -44.48819, "earningsTimestamp": 1733833800, "earningsTimestampStart": 1742301000, "earningsTimestampEnd": 1742819400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.01, "epsForward": -1.94, "epsCurrentYear": -1.0135, "priceEpsCurrentYear": -1.420819, "fiftyDayAverageChange": 0.4136201, "fiftyDayAverageChangePercent": 0.40298927, "twoHundredDayAverageChange": -0.19929993, "twoHundredDayAverageChangePercent": -0.12157624, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-03-25", "averageAnalystRating": "2.5 - Buy", "shortName": "LAVA Therapeutics N.V.", "longName": "LAVA Therapeutics N.V.", "cryptoTradeable": false, "corporateActions": [], "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1616765400000, "displayName": "LAVA Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-03-08"}]